EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Analytical and clinical validation of the Lumipulse G plasma p‐tau217 assay for clinical implementation

Burak Arslan iD, Johan Gobom, Ulf Andreasson, Laia Montoliu-Gaya, Andrea L Benedet, Anna Dittrich, Silke Kern, Ingmar Skoog, Nicholas J Ashton, Tevy Chan, Nesrine Rahmouni, Pedro Rosa-Neto und 3 weitere

Alzheimer's & Dementia · 2026

DOI: 10.1002/alz.71374 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Burak Arslan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal…. Hauptthemen laut MEDLINE: tau Proteins, Alzheimer Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Gothenburg, Swedish Research Council, European Union's Horizon Europe research and innovation programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Although several plasma tau phosphorylated at threonine 217 (p‐tau217) immunoassays are now available, comprehensive analytical validation remains limited. We therefore evaluated the Lumipulse G plasma p‐tau217 assay and verified established cutoffs for clinical implementation. METHODS This study was conducted in two phases: (1) analytical validation of the Lumipulse G plasma p‐tau217 assay, assessing precision, lower limit of quantification (LLoQ), selectivity, stability, and interference; and (2) verification of previously established cutoffs using a two‐threshold approach in 37 samples with confirmed cerebrospinal fluid (CSF) Aβ42/Aβ40 status. RESULTS The assay demonstrated strong analytical performance, with repeatability and intermediate precision (%CV < 7%) and an LLoQ of 0.12 pg/mL. The p‐tau217 was stable across freeze–thaw cycles but less so at 4°C, and hemolysis > 2% introduced variability. Cutoff verification showed 97% reproducibility with excellent agreement ( ρ = 0.99, p < 0.0001). DISCUSSION The Lumipulse assay showed robust analytical performance and reproducibility, supporting clinical use, though certified reference materials are still needed for standardization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsAlzheimer DiseaseHumansReproducibility of ResultsPhosphorylationImmunoassayAmyloid beta-PeptidesBiomarkers

Stichwörter der Autor:innen

Alzheimer's diseaseanalytical validationlumipulseplasmap‐tau217

Substanzen

tau ProteinsAmyloid beta-PeptidesBiomarkers

Autor:innen und Institutionen

  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Department of Neuropsychiatry, Region Västra Götaland, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Banner Sun Health Research Institute, Sun City, Arizona, USA.
  • Banner Alzheimer's Institute, Phoenix, Arizona, USA.
  • Translational Neuroimaging Laboratory, Montreal Neurological Institute-Hospital, Montreal, Canada.

ORCID-Profile: Burak Arslan

Förderung

  • University of Gothenburg
  • Swedish Research Council
  • European Union's Horizon Europe research and innovation programme
  • Swedish State Support for Clinical Research
  • AD Strategic Fund
  • Alzheimer's Association
  • Bluefield Project
  • Cure Alzheimer's Fund

Zitieren

APA

Arslan, B., Gobom, J., Andreasson, U., Montoliu-Gaya, L., Benedet, A. L., Dittrich, A., Kern, S., Skoog, I., Ashton, N. J., Chan, T., Rahmouni, N., Rosa-Neto, P., Blennow, K., Zetterberg, H., & Kvartsberg, H. (2026). Analytical and clinical validation of the Lumipulse G plasma p‐tau217 assay for clinical implementation. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71374

Vancouver

Arslan B, Gobom J, Andreasson U, Montoliu-Gaya L, Benedet AL, Dittrich A, et al. Analytical and clinical validation of the Lumipulse G plasma p‐tau217 assay for clinical implementation. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71374

BibTeX
@article{Arslan2026,
  author = {Arslan, Burak and Gobom, Johan and Andreasson, Ulf and Montoliu-Gaya, Laia and Benedet, Andrea L and Dittrich, Anna and Kern, Silke and Skoog, Ingmar and Ashton, Nicholas J and Chan, Tevy and Rahmouni, Nesrine and Rosa-Neto, Pedro and Blennow, Kaj and Zetterberg, Henrik and Kvartsberg, Hlin},
  title = {Analytical and clinical validation of the Lumipulse G plasma p‐tau217 assay for clinical implementation},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  doi = {10.1002/alz.71374}
}
Kostenlos starten →